Ferric derisomaltose is an iron injection used in the treatment of iron deficiency anemia. Iron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide.
- Mechanism
- Curator reviewed · 3 references
This drug is a complex made of iron (III) hydroxide and derisomaltose, which is an iron carbohydrate oligosaccharide that works to releases iron. The released iron then binds to the transport protein, transferrin, and is taken to erythroid precursor cells for incorporation into the hemoglobin molecule.
- Primary indication
- This drug is indicated for the treatment of iron deficiency anemia in adult patients who have experienced intolerance to oral iron preparations or insufficient clinical response to orally administered iron.Curator reviewed · 4 structured indications
- Formula / weight
- C18H34FeO16 · 562.297 g/mol (avg)
- First approval
- Canada, 2021 · United States, 2020
- Also known as
- iron isomaltoside
- Code names
- NS32 · RVG 103070 · WHO 9712
Resolves to
Compound
Clinical / RWD
Structure
InChIKey
JTQTXQSGPZRXJF-DOJSGGEQSA-NSMILES[Fe+3].OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1OTargets
What you can answer from here — as of August 31, 2026
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
1TransporterSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Ferric derisomaltose, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account